• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA• Launch preparations are underway to bring the second approved golimumab biosimilar to patients acro...
View DetailsGUANGZHOU, China, September 27,2021 (BUSINESSWIRE) –Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”)and Intract Pharma (“Intract”) announced a global collaboration and licensingagreement that gives Bio-Thera access to Intract’s Soteria® and Phloral...
®Under the agreement, Bio-Thera will maintain responsibilities for development, manufacturing, and supply of BAT1706. Sandoz will commercialize the medicine in all markets covered by the agreement upon regulatory approval. The license covers the US, ...
Guangzhou and London, 27 August2021–Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody t...
